Pharming Group N.V. ADR (PHAR)

$12.90 3.08 (19.27%)

16:00 EDT PHAR Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Sep 22, 2023

Pre-market stock movers are a hot topic this morning and we're checking on the biggest ones investors will want to watch on Friday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 23,103

Day's Range $12.86 - $13.24

52-Week Range $8.65 - $17.81

Dividend & Yield N/A (N/A)

PHAR Stock Predictions, Articles, and Pharming Group N.V. ADR News

From the Web

Pharming sells rare pediatric disease PRV to Novartis for $21.1M (NASDAQ:PHAR)

From Seeking Alpha Jun 1, 2023

Pharming Group (PHAR) has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher, the company said Thursday.

Pharming GAAP EPS of -$0.01, revenue of $42.54M (NASDAQ:PHAR)

From Seeking Alpha May 11, 2023

Pharming press release (PHAR): Q1 GAAP EPS of -$0.017.Revenue of $42.54M (-8.8% Y/Y).

Pharming wins FDA nod for immune disorder therapy (NASDAQ:PHAR)

From Seeking Alpha Mar 27, 2023

Dutch biotech Pharming Group (PHAR) has received FDA approval for rare immune disorder therapy Joenja co-developed with Novartis (NVS). Read more here.

Pharming's leniolisib review converted to standard from accelerated as EMA seeks more data

From Seeking Alpha Feb 16, 2023

A panel of the European Medicines Agency ((EMA)) converted the review of Pharming's (PHAR) drug leniolisib to standard review from accelerated assessment as the committee sent questions...

Pharming reports publishing of phase 3 data of rare immunodeficiency disorder drug

From Seeking Alpha Dec 7, 2022

Pharming (PHAR) said data from a phase 3 trial of its drug to treat adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome ((APDS)) were published in...

H.C. Wainwright Reaffirms Their Buy Rating on Pharming Group (PHAR)

From TipRanks Oct 27, 2022

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of $37.00. The compan...